Background and Purpose—The term symptomatic hemorrhage secondary to ischemic
stroke implies a clear causal relationship between clinical deterioration and hemorrhagic …

Background Intravenous thrombolysis with alteplase is the only approved treatment for acute
ischemic stroke, but its efficacy and safety when administered more than 3 hours after the …

Background We aimed to assess the safety and efficacy of thrombectomy for the treatment
of stroke in a trial embedded within a population-based stroke reperfusion registry. Methods …

Background Thrombolysis for acute ischaemic stroke has been investigated in several
clinical trials, with variable results. We have assessed the safety and efficacy of intravenous …

Objective. —To evaluate the efficacy and safety of intravenous thrombolysis using recombinant
tissue plasminogen activator (rt-PA) in patients with acute ischemic stroke. Design. —…

Background Early administration of intravenous recombinant tissue plasminogen activator (rt-PA)
after ischaemic stroke improves outcome. Previous analysis of combined data from …

Background Endovascular therapy is increasingly used after the administration of intravenous
tissue plasminogen activator (t-PA) for patients with moderate-to-severe acute ischemic …

Background and Purpose—Intravenous thrombolysis with recombinant tissue plasminogen
activator (rtPA) improves the outcome for ischemic stroke patients who can be treated within …

Background: Although the clinical features of space-occupying ischemic stroke are well
known, there are limited prospective data on the clinical course of complete middle cerebral …

Methods A hybrid approach based on established processes described by Glaser15 and by
the National Institutes of Health (http://prevention. nih. gov/cdp/about. aspx) 16 was used to …